Lazard Upgrades Amylin (AMLN) to Buy
More News related to AMLN
- Unusual 11 Mid-Day Movers 11/17: GTE, CTS, PHH, ARTG Higher; UTHR, DFT, BIDU, HIG Lower
- Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
- Canaccord Adams Maintains 'Hold' Rating on Amylin Pharmaceuticals (AMLN), Lowers Price Target
- Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
- Amylin Pharma (AMLN) Sees Morning Pressure
More News related to Upgrades
- ION Geophysical (IO) Director Buys 50K Shares
- Sunstone Hotel Investors (SHO) CFO Buys 20K Shares
- Dillard's (DDS) Director White Buys 27K Shares
- Strategic Hotels & Resorts (BEE) CEO Buys 39.5K Shares
- Caribou Coffee (CBOU) CEO Buys 11.9K Shares
Lazard Capital upgrades Amylin Pharmaceutical (Nasdaq: AMLN) from Hold to Buy.
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States.
Related Categories
UpgradesStocks Mentioned
+0.00
-1.35Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
